The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,007
Wijnands, J. M. A., Kingwell, E., Zhu, F., Zhao, Y., Högg, T., Stadnyk, K., Ekuma, O., Lu, X., Evans, C. D., Fisk, J. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30076-5 · Cited by 160
Longitudinal Assessment of Multiple Sclerosis with the Brain‐Age Paradigm
Cole, J. H., Raffel, J., Friede, T., Eshaghi, A., Brownlee, W. J., Chard, D., Stefano, N. D., Enzinger, C., Pirpamer, L., Filippi, M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25746 · Cited by 158
Self-citationDysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Rommer, P. S., Eichstädt, K., Ellenberger, D., Flachenecker, P., Friede, T., Haas, J., Kleinschnitz, C., Pöhlau, D., Rienhoff, O., Stahmann, A., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518799580 · Cited by 152
Therapeutic Potential of ω-3 Polyunsaturated Fatty Acids in Human Autoimmune Diseases
Li, X., Bi, X., Wang, S., Zhang, Z., Li, F., & Zhao, A. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02241 · Cited by 157
The topographical model of multiple sclerosis
Krieger, S. C., Cook, K., Nino, S. D., & Fletcher, M. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000279 · Cited by 154
The role of diet in multiple sclerosis: A review
Esposito, S., Bonavita, S., Sparaco, M., Gallo, A., & Tedeschi, G. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1303016 · Cited by 158
Continuous daily assessment of multiple sclerosis disability using remote step count monitoring
Block, V. J., Lizée, A., Crabtree‐Hartman, E., Bevan, C. J., Graves, J., Bove, R. M., Green, A. J., Nourbakhsh, B., Tremblay, M. A., Gourraud, P., et al. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8334-6 · Cited by 148
Gholamzad, M., Ebtekar, M., Ardestani, M. S., Azimi, M., Mahmodi, Z., Mousavi, M. J., & Aslani, S. (2018) · Inflammation Research · doi:10.1007/s00011-018-1185-0 · Cited by 161
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman, L. A., Longbrake, E. E., Coyle, P. K., Hendin, B. A., & Vollmer, T. R. (2022) · CNS Drugs · doi:10.1007/s40263-022-00965-7 · Cited by 155
Cadavid, D., Cohen, J. A., Freedman, M. S., Goldman, M. D., Hartung, H.-P., Havrdová, E., Jeffery, D., Kapoor, R., Miller, A., Sellebjerg, F. T., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516638941 · Cited by 145
Self-citationTowards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalinčík, T., Manouchehrinia, A., Sobíšek, L., Jokubaitis, V., Spelman, T. D., Horáková, D., Havrdová, E., Trojano, M., Izquierdo, G., Lugaresi, A., et al. (2017) · Brain · doi:10.1093/brain/awx185 · Cited by 145
Assessment and impact of cognitive impairment in multiple sclerosis: An overview
Macías Islas, M. Á., & Ciampi, E. (2019) · Biomedicines · doi:10.3390/biomedicines7010022 · Cited by 144
Kamma, E., Lasisi, W. O., Libner, C. D., Ng, H. S., & Plemel, J. R. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02408-y · Cited by 157
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome
Okuda, D. T., Kantarci, O. H., Lebrun‐Frénay, C., Sormani, M. P., Azevedo, C. J., Bovis, F., Hua, L. H., Amezcua, L., Mowry, E. M., Hotermans, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26555 · Cited by 153
Self-citationThe role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis
Mallucci, G., Peruzzotti‐Jametti, L., Bernstock, J. D., & Pluchino, S. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.02.003 · Cited by 153
Therapeutic Advances in Multiple Sclerosis
Yang, J. H., Rempe, T., Whitmire, N., Dunn‐Pirio, A., & Graves, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.824926 · Cited by 148
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression
Moccia, M., Lanzillo, R., Palladino, R., Chang, K., Costabile, T., Russo, C. V., Rosa, A. D., Carotenuto, A., Saccà, F., Maniscalco, G. T., et al. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515599075 · Cited by 141
Both cladribine and alemtuzumab may effect MS via B-cell depletion
Baker, D., Herrod, S. S., Álvarez-González, C., Zalewski, L., Albor, C., & Schmierer, K. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000360 · Cited by 140
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets
Forsthuber, T. G., Cimbora, D. M., Ratchford, J. N., Katz, E., & Stüve, O. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418761697 · Cited by 143
Self-citationA focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition
Inojosa, H., Proschmann, U., Akgün, K., & Ziemssen, T. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09489-5 · Cited by 152
Marziniak, M., Brichetto, G., Feys, P., Meyding‐Lamadé, U., Vernon, K., & Meuth, S. G. (2018) · JMIR Rehabilitation and Assistive Technologies · doi:10.2196/rehab.7805 · Cited by 136
Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Boutitah-Benyaich, I., Eixarch, H., Villacieros‐Álvarez, J., Hervera, A., Cobo‐Calvo, Á., Montalbán, X., & Espejo, C. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02415-4 · Cited by 149
The role of chemokines and chemokine receptors in multiple sclerosis
Cui, L.-Y., Chu, S.-F., & Chen, N.-H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106314 · Cited by 135
Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI
Absinta, M., Sati, P., Fechner, A., Schindler, M. K., Nair, G., & Reich, D. S. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5660 · Cited by 140
Resolution of inflammation during multiple sclerosis
Ruiz, F., Vigne, S., & Pot, C. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00765-0 · Cited by 136
Keller, H., de van der Schueren, M. A. E., for the GLIM Consortium, Jensen, G. L., Barazzoni, R., Compher, C., Correia, M. I. T. D., Gonzalez, M. C., Jager‐Wittenaar, H., Pirlich, M., et al. (2020) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.1806 · Cited by 131
Aging-suppressor Klotho: Prospects in diagnostics and therapeutics
Abraham, C. R., & Li, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101766 · Cited by 133
Mechanisms of glutamate toxicity in multiple sclerosis: biomarker and therapeutic opportunities
Macrez, R., Stys, P. K., Vivien, D., Lipton, S. A., & Docagne, F. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30165-x · Cited by 127
The 2013 clinical course descriptors for multiple sclerosis
LUBLIN, F. D., Coetzee, T., Cohen, J. A., Marrie, R. A., & Thompson, A. J. (2020) · Neurology · doi:10.1212/wnl.0000000000009636 · Cited by 138
Self-citationKahroba, H., Ramezani, B., Maadi, H., Sadeghi, M. R., Jaberie, H., & Ramezani, F. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101211 · Cited by 130
Zabalza, A., Cárdenas‐Robledo, S., Tagliani, P., Arrambide, G., Otero‐Romero, S., Carbonell‐Mirabent, P., Rodríguez, M., Rodríguez‐Acevedo, B., Restrepo‐Vera, J. L., Resina-Salles, M., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14690 · Cited by 131
Aggressive multiple sclerosis: proposed definition and treatment algorithm
Rush, C., MacLean, H. J., & Freedman, M. S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.85 · Cited by 128
Self-citationFatigue Management in Multiple Sclerosis
Tur, C. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0411-8 · Cited by 127
Cortese, M., Riise, T., Bjørnevik, K., Bhan, A., Farbu, E., Grytten, N., Hogenesch, I., Midgard, R., Simonsen, C. S., Telstad, W., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24769 · Cited by 132
Peres, D. S., Rodrigues, P., Viero, F. T., Frare, J. M., Kudsi, S. Q., Meira, G. M., & Trevisan, G. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100484 · Cited by 134
McKay, K. A., Kwan, V., Duggan, T., & Tremlett, H. L. (2015) · BioMed Research International · doi:10.1155/2015/817238 · Cited by 135
An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders
Alghamdi, M. A., Alasmari, D., Assiri, A., Mattar, E. H., Aljaddawi, A. A., Alattas, S. G., & Redwan, E. M. M. M. (2019) · Journal of Immunology Research · doi:10.1155/2019/7592851 · Cited by 129
Chataway, J., Angelis, F. D., Connick, P., Parker, R. A., Plantone, D., Doshi, A., John, N. A., Stutters, J., MacManus, D. G., Prados, F., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30485-5 · Cited by 126
Self-citationGuo, C., Ferreira, D., Fink, K., Westman, E., & Granberg, T. (2018) · European Radiology · doi:10.1007/s00330-018-5710-x · Cited by 130
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Treatment of Acute Relapses in Multiple Sclerosis
Berkovich, R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0160-7 · Cited by 125
Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology
Kukanja, P., Langseth, C. M., Rubio Rodríguez-Kirby, L. A., Agirre, E., Zheng, C., Raman, A., Yokota, C., Avenel, C., Tiklová, K., Guerreiro-Cacais, A. O., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.030 · Cited by 124
The gut microbiota in multiple sclerosis varies with disease activity
Thirion, F., Sellebjerg, F. T., Fan, Y., Lyu, L., Hansen, T. H., Pons, N., Levenez, F., Quinquis, B., Stankevič, E., Søndergaard, H. B., et al. (2023) · Genome Medicine · doi:10.1186/s13073-022-01148-1 · Cited by 133
Self-citationApplication of network methods for understanding mental disorders: pitfalls and promise
Gülöksüz, S., Pries, L.-K., & van Os, J. (2017) · Psychological Medicine · doi:10.1017/s0033291717001350 · Cited by 132
Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI
Narayana, P. A., Coronado, I., Sujit, S. J., Wolinsky, J. S., LUBLIN, F. D., & Gabr, R. E. (2019) · Radiology · doi:10.1148/radiol.2019191061 · Cited by 127
Self-citationPrediction of disease progression and outcomes in multiple sclerosis with machine learning
Pinto, M. F., Oliveira, H., Batista, S., Cruz, L., Pinto, M., Correia, I., Martins, P., & Teixeira, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-78212-6 · Cited by 122
Structural MRI correlates of cognitive impairment in patients with multiple sclerosis
Preziosa, P., Rocca, M. A., Pagani, E., Stromillo, M. L., Enzinger, C., Gallo, A., Hulst, H. E., Atzori, M., Pareto, D., Riccitelli, G. C., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23125 · Cited by 121
Self-citationKooij, G., Troletti, C. D., Leuti, A., Norris, P. C., Riley, I. R., Albanese, M., Ruggieri, S., Libreros, S., van der Pol, S. M. A., Hof, B. V. H., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.219519 · Cited by 123
Viral infections and their relationship to neurological disorders
Wouk, J., Rechenchoski, D. Z., Rodrigues, B. C. D., Ribelato, E. V., & Galhardi, L. C. F. (2021) · Archives of Virology · doi:10.1007/s00705-021-04959-6 · Cited by 123
Cawley, N., Solanky, B., Muhlert, N., Tur, C., Edden, R. A. E., Wheeler‐Kingshott, C. A. M. G., Miller, D. H., Thompson, A. J., & Ciccarelli, O. (2015) · Brain · doi:10.1093/brain/awv209 · Cited by 125
Self-citationIaffaldano, P., Lucisano, G., Caputo, F., Paolicelli, D., Patti, F., Zaffaroni, M., Morra, V. B., Pozzilli, C., Luca, G. D., Inglese, M., et al. (2021) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864211019574 · Cited by 123
Self-citationThinking outside the box: non-canonical targets in multiple sclerosis
Bierhansl, L., Hartung, H., Aktaş, O., Ruck, T., Roden, M., & Meuth, S. G. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00477-5 · Cited by 125
Role of Viruses in the Pathogenesis of Multiple Sclerosis
Tarlinton, R. E., Martynova, E. V., Rizvanov, A. A., Khaiboullina, S. F., & Verma, S. C. (2020) · Viruses · doi:10.3390/v12060643 · Cited by 121
Rahmanzadeh, R., Lu, P., Baraković, M., Weigel, M., Maggi, P., Nguyen, T. D., Schiavi, S., Daducci, A., Rosa, F. L., Schaedelin, S. A., et al. (2021) · Brain · doi:10.1093/brain/awab088 · Cited by 121
Self-citationThe neural stem cell secretome and its role in brain repair
Willis, C. M., Nicaise, A. M., Peruzzotti‐Jametti, L., & Pluchino, S. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146615 · Cited by 119
Efficacy classification of modern therapies in multiple sclerosis
Samjoo, I. A., Worthington, E., Drudge, C., Zhao, M., Cameron, C. G., Häring, D. A., Stoneman, D., Klotz, L., & Adlard, N. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0267 · Cited by 120
Schwartzbach, C. J., Grove, R. A., Brown, R. A., Tompson, D. J., Bergh, F. T., & Arnold, D. L. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8341-7 · Cited by 116
Giovannoni, G., Cutter, G., Sormani, M. P., Belachew, S. M., Hyde, R., Koendgen, H., Knappertz, V. A., Tomic, D., Leppert, D., Herndon, R. M., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.01.007 · Cited by 116
Self-citationShinohara, R. T., Oh, J., Nair, G., Calabresi, P. A., Davatzikos, C. A., Doshi, J. J., Henry, R. G., Kim, G., Linn, K. A., Papinutto, N., et al. (2017) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5254 · Cited by 116
Self-citationHighly active multiple sclerosis: An update
Díaz, C., Zarco, L. A., & Rivera, D. M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.01.039 · Cited by 123
What Can We Learn from Sex Differences in MS?
Coyle, P. K. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101006 · Cited by 132
Duffy, S. S., Lees, J. G., & Moalem‐Taylor, G. (2014) · Multiple Sclerosis International · doi:10.1155/2014/285245 · Cited by 118
Riboflavin in Neurological Diseases: A Narrative Review
Plantone, D., Pardini, M., & Rinaldi, G. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01038-1 · Cited by 115
Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases
Wildner, P., Stasiołek, M., & Matysiak, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101452 · Cited by 119
Cree, B., Cutter, G., Wolinsky, J. S., Freedman, M. S., Comı, G., Giovannoni, G., Hartung, H.-P., Arnold, D. L., Kühle, J., Block, V. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30347-1 · Cited by 113
Self-citationThe complex relationship between obesity and neurodegenerative diseases: an updated review
Neto, A., Fernandes, A. M. A., & Barateiro, A. P. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1294420 · Cited by 120
Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses
Zalewski, N. L., Flanagan, E. P., & Keegan, B. M. (2017) · Neurology · doi:10.1212/wnl.0000000000004796 · Cited by 112
Nrf2/ARE Pathway Modulation by Dietary Energy Regulation in Neurological Disorders
Vasconcelos, A. R., dos Santos, N. B., Scavone, C., & Munhoz, C. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00033 · Cited by 113
Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes
Reynders, T., Devolder, L., Valles‐Colomer, M., Remoortel, A. V., Joossens, M., Keyser, J. D., Nagels, G., D'hooghe, M. B., & Raes, J. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51004 · Cited by 113
Mirmosayyeb, O., Brand, S., Barzegar, M., Afshari-Safavi, A., Nehzat, N., Shaygannejad, V., & Bahmani, D. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051326 · Cited by 116
Multiple sclerosis: New insights and trends
Koriem, K. M. M. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.009 · Cited by 112
Uccelli, A., Laroni, A., Ali, R., Battaglia, M. A., Blinkenberg, M., Brundin, L., Clanet, M., Fernández, Ó., Marriott, J. J., Muraro, P. A., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00301-x · Cited by 110
Self-citationDeterminants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
Calabrese, M., Preziosa, P., Scalfari, A., Colato, E., Marastoni, D., Absinta, M., Battaglini, M., Stefano, N. D., Filippo, M. D., Hametner, S., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26913 · Cited by 115
Self-citationCohen, J. A., Baldassari, L. E., Atkins, H. L., Bowen, J. D., Bredeson, C., Carpenter, P. A., Corboy, J. R., Freedman, M. S., Griffith, L. M., Lowsky, R., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.02.014 · Cited by 108
Self-citationMetabolomic signatures associated with disease severity in multiple sclerosis
Villoslada, P., Alonso, C., Agirrezabal, I., Kotelnikova, E. A., Zubizarreta, I., Valdeolivas, I. P., Saiz, A., Comabella, M., Montalbán, X., Villar, L. M., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000321 · Cited by 107
Multiple Sclerosis Diagnosis Using Machine Learning and Deep Learning: Challenges and Opportunities
Aslam, N., Khan, I. U., Bashamakh, A., Alghool, F. A., Aboulnour, M., Alsuwayan, N. M., Alturaif, R. K., Brahimi, S., Aljameel, S. S., & Ghamdi, K. S. A. (2022) · Sensors · doi:10.3390/s22207856 · Cited by 109
Body fluid biomarkers for multiple sclerosis—the long road to clinical application
Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., & Killestein, J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.173 · Cited by 106
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder
Müller, J., Sinnecker, T., Wendebourg, M. J., Schlaeger, R., Kühle, J., Schädelin, S., Benkert, P., Derfuss, T. J., Cattin, P. C., Jud, C., et al. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001147 · Cited by 105
Self-citationCerebellar Dysfunction in Multiple Sclerosis
Wilkins, A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00312 · Cited by 104
Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD
Cortese, R., Magnollay, L., Tur, C., Abdel‐Aziz, K., Jacob, A., Angelis, F. D., Yiannakas, M. C., Prados, F., Sebastien Ourselin, A., Yousry, T. A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005256 · Cited by 104
Self-citationWillekens, B. M. P., Presas‐Rodríguez, S., Mansilla, M. J., Derdelinckx, J., Lee, W.-P., Nijs, G., Laere, M. D., Wens, I., Cras, P. P., Parizel, P. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030309 · Cited by 108
Identifying Progression in Multiple Sclerosis: New Perspectives
Filippi, M., Preziosa, P., Langdon, D. W., Lassmann, H., Paul, F., Rovira, À., Schoonheim, M. M., Solari, A., Stankoff, B., & Rocca, M. A. (2020) · Annals of Neurology · doi:10.1002/ana.25808 · Cited by 104
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis
Novotná, M., Soldán, M. M. P., Zeid, N. E. A., Kale, N., Tütüncü, M., Crusan, D. J., Atkinson, E. J., Sıva, A., Keegan, B. M., Pirko, I., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001856 · Cited by 109
Multiple sclerosis: Serum-derived exosomes express myelin proteins
Gałązka, G., Mycko, M. P., Selmaj, I., Raine, C. S., & Selmaj, K. W. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517696597 · Cited by 103
Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature
Jeong, A., Oleske, D. M., & Holman, J. (2019) · Journal of Child Neurology · doi:10.1177/0883073819845827 · Cited by 107
Miller, E. D., Dziedzic, A., Saluk, J., & Bijak, M. (2019) · Nutrients · doi:10.3390/nu11071528 · Cited by 106
Inhibition of CD40L with frexalimab in multiple sclerosis
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Truffinet, P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309439 · Cited by 102
Self-citationYamout, B., Sahraian, M. A., Bohlega, S., Aljumah, M., Gouider, R., Dahdaleh, M., Inshasi, J. S. S., Hashem, S., Alsharoqi, I., Khoury, S. J., et al. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101459 · Cited by 107
Multiple Sclerosis: Inflammatory and Neuroglial Aspects
Papiri, G., D’Andreamatteo, G., Cacchiò, G., Alia, S., Silvestrini, M., Paci, C., Luzzi, S., & Vignini, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020094 · Cited by 107
Immunosenescence in multiple sclerosis: the identification of new therapeutic targets
Dema, M. G., Eixarch, H., Villar, L. M., Montalbán, X., & Espejo, C. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102893 · Cited by 103
Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma
Ntranos, A., Park, H.-J., Wentling, M., Tolstikov, V., Amatruda, M., Inbar, B., Kim‐Schulze, S., Frazier, C., Button, J., Kiebish, M. A., et al. (2021) · Brain · doi:10.1093/brain/awab320 · Cited by 108
Self-citationScalfari, A., Traboulsee, A. L., Oh, J., Airas, L. M., Bittner, S., Calabrese, M., García‐Domínguez, J. M., Granziera, C., Greenberg, B. M., Hellwig, K., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27034 · Cited by 107
Neutrophils: Underestimated Players in the Pathogenesis of Multiple Sclerosis (MS)
Bondt, M. D., Hellings, N., Opdenakker, G., & Struyf, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124558 · Cited by 104
Optimizing therapy early in multiple sclerosis: An evidence-based view
Ziemssen, T., Stefano, N. D., Sormani, M. P., Wijmeersch, B. V., Wiendl, H., & Kieseier, B. C. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.07.007 · Cited by 103
Self-citationEpidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis
Yan, K., Balijepalli, C., Desai, K., Gullapalli, L., & Druyts, E. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102260 · Cited by 101
Win odds: An adaptation of the win ratio to include ties
Brunner, E., Vandemeulebroecke, M., & Mütze, T. (2021) · Statistics in Medicine · doi:10.1002/sim.8967 · Cited by 99
Greco, R., Alexander, T., Papa, N. D., Müller, F., Saccardi, R., Sanchez-Guijo, F. M., Schett, G. A., Sharrack, B., Snowden, J. A., Tarte, K., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102476 · Cited by 104
Dietary interventions for multiple sclerosis-related outcomes
Parks, N. E., Jackson-Tarlton, C. S., Vacchi, L., Merdad, R. A., & Johnston, B. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004192.pub4 · Cited by 100
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
